INS and type 1 diabetes mellitus: The primary aim is to test the hypothesis that treatment with insulin degludec as compared to insulin glargine U100 results in lower risk of symptomatic nocturnal hypoglycaemia in patients with type 1 diabetes and high risk of severe nocturnal hypoglycaemia.